The Biotech Trader Handbook (2nd Edition): A Fast, Simplified & Efficient Guide to Potentially Generate Outsized Returns in Biotech Using Options (for (Paperback) - Common

Small cap biotech companies spend hundreds of millions of dollars and over ten years moving experimental drug candidates from concept to fully approved drugs. For late stage drug candidates, those in Phase III, positive or negative data can result in either massive gains or devastating declines in the sponsoring company's stock price. This "ultimate catalyst event" provides smart, organized & nimb...